Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.21
    +1.19 (+10.80%)

    Market Cap: $1.86B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(12/30)
    Avg Surprise
    -6.96%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-2.23
    Range$-2.68 - $-1.83
    6 analysts
    Revenue Consensus
    $-93754710
    Range$-133235000 - $-73935000
    8 analysts
    Last 12 of 30 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-2.23$-2.68 - $-1.83--6--
    Sep 26
    Reported Nov 4
    		$-0.57$-0.80$-0.95 - $-0.58+28.75%Beat6
    2
    2
    30d
    		+51.3%
    Jun 26
    Reported Aug 5
    		$0.47$0.83$0.47 - $0.83-43.37%Miss4
    No revisions (30d)
    		+158.8%
    Mar 26
    Reported May 6
    		$-0.85$0.48$-0.59 - $1.05-277.08%Miss4
    1
    2
    30d
    		+3.4%
    Dec 25
    Reported Feb 23
    		$-0.31$-0.54$-0.78 - $-0.16+42.59%Beat7
    2
    0
    30d
    		+59.2%
    Sep 25
    Reported Nov 5
    		$-1.17$-0.70$-1.32 - $-0.60-67.14%Miss7
    1
    3
    30d
    		+25.0%
    Jun 25
    Reported Aug 6
    		$-0.80$-0.72$-0.88 - $-0.54-11.11%Miss7
    5
    1
    30d
    		+21.6%
    Mar 25
    Reported May 7
    		$-0.88$-0.84$-1.03 - $-0.67-4.76%Miss6
    0
    1
    30d
    		-83.3%
    Dec 24
    Reported Feb 26
    		$-0.76$-0.89$-0.96 - $-0.66+14.61%Beat7
    No revisions (30d)
    		+11.6%
    Sep 24
    Reported Oct 31
    		$-1.56$-1.08$-1.75 - $-0.85-44.44%Miss8
    No revisions (30d)
    		-27.9%
    Jun 24
    Reported Aug 1
    		$-1.02$-0.89$-1.10 - $-0.54-14.61%Miss8
    No revisions (30d)
    		+29.7%
    Mar 24
    Reported May 2
    		$-0.48N/A-+54.29%Beat7
    No revisions (30d)
    		+54.7%
    Dec 23
    Reported Feb 22
    		$-0.86$-1.01$-1.26 - $-0.40+14.85%Beat9
    No revisions (30d)
    		-13.2%

    Key Metrics

    Valuation
    P/E Ratio-9.69EV/EBITDAN/A
    Price/FCF-14.57xFCF Yield-6.86%
    Profitability
    Profit Margin-83.00%Operating Margin30.70%
    ROE-26.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.30xQuick Ratio6.30x
    Trading Statistics
    Beta1.74Avg Volume1.76M
    52-Week High$12.1952-Week Low$5.22

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.48
    SMA 20$11.00
    SMA 50$11.03
    SMA 200$9.64
    EMA 10$11.41
    EMA 20$11.22
    EMA 50$10.88
    EMA 200$9.51

    MACD

    Line: 0.21Signal: 0.13Hist: 0.08

    ADX

    ADX: 18.3+DI: 26.7-DI: 13.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down40.0
    PSAR$10.93

    Bollinger Bands

    Upper Band$12.24
    Lower Band$9.77
    %B Position2251%(Upper)
    Band Width0.99

    RSI (14-Day)

    Neutral
    59.9

    Momentum Oscillators

    Stoch %K73.1
    Stoch %D65.9
    Williams %R-9.7
    ROC (10d)15.5%
    Momentum1.64
    CCI (20d)130.8
    MFI (14d)65.5

    Volatility Measures

    ATR (14d)$0.71(5.8%)
    StdDev (20d)0.62
    Hist Vol70.6%(High)

    Volume Flow

    VWAP$11.98
    OBV35.4M
    AD Line-23.9M
    CMF (20d)-0.053

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.1x
    VWMA (20d)$11.04

    Pivot Points

    R3$12.97
    R2$12.57
    R1$11.79
    Pivot Point$11.39
    S1$10.61
    S2$10.21
    S3$9.43

    Advanced Oscillators

    TSI8.84
    Ultimate Osc48.9
    KST36.17

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$-188,000$238.95M$0$64.31M$240,000$1.21M$3.03M$12.37M$2.38M$3.08M$56.38M$16.79M
    Cost of Revenue$0$0$0$15,000$0$11,000$0$684,000$50,000$52,000$59,000$798,000
    Gross Profit$-188,000$238.95M$0$64.30M$240,000$1.20M$3.03M$11.69M$2.33M$3.02M$56.32M$15.99M
    Operating Expenses$104.47M$165.48M$132.26M$111.97M$173.68M$119.62M$142.58M$128.84M$233.63M$161.65M$136.40M$155.00M
    R&D$80.04M$135.28M$108.92M$88.35M$151.46M$97.51M$118.64M$106.08M$195.18M$105.11M$100.13M$108.97M
    SG&A$24.43M$30.20M$23.34M$23.62M$22.23M$22.28M$23.94M$26.70M$25.74M$30.27M$36.32M$41.22M
    Operating Income$-104,658,000$73.47M$-132,290,000$-47,921,000$-173,443,000$-118,417,000$-139,547,000$-117,150,000$-231,304,000$-158,630,000$-80,081,000$-139,016,000
    Interest Income$9.32M$8.97M$7.19M$7.80M$9.36M$10.79M$12.29M$14.15M$17.53M$18.85M$21.28M$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-96,395,000$80.26M$-125,525,000$-43,060,000$-162,973,000$-110,788,000$-120,949,000$-104,675,000$-213,540,000$-139,890,000$-65,000,000$-120,757,000
    Income Tax Expense$-143,000$179,000$170,000$-137,000$168,000$170,000$16,000$-86,000$177,000$-1,512,000$276,000$-4,784,000
    Net Income$-96,252,000$80.08M$-125,695,000$-42,923,000$-163,141,000$-110,958,000$-120,965,000$-104,589,000$-213,717,000$-138,378,000$-65,276,000$-115,973,000
    EBITDA$-103,690,000$74.42M$-129,509,000$-46,415,000$-168,023,000$-116,135,000$-126,281,000$-113,774,000$-227,817,000$-151,839,000$-81,528,000$-135,663,000
    EBIT$-105,718,000$71.29M$-132,714,000$-50,862,000$-172,336,000$-121,573,000$-133,237,000$-118,828,000$-231,067,000$-158,736,000$-86,283,000$-141,493,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VIR

    Government Contracts

    Gov Obligations (TTM)
    -$8.36M
    Gov Obligations / Revenue
    -12.8%
    Obligations YoY
    80.1%
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Vir Biotechnology stock hits 52-week high at 12.19 USD By Investing.com

    Vir Biotechnology Inc. (VIR) has achieved a 52-week high of $12.19, reflecting a significant 137.23% appreciation over the past year and an 83% year-to-date return. Despite this surge and a market capitalization of $2.09...

    Investing.com Canada•11/6/26•Bullish

    This Insider Has Just Sold Shares In Vir Biotechnology

    Vir Biotechnology's Executive VP, Vanina de Verneuil, recently sold US$42k worth of stock at US$11.18 per share...

    Simply Wall St•11/6/26•Somewhat-Bearish

    Vir Biotechnology Narrows Third-Quarter Net Loss to $96.3 Million

    Vir Biotechnology reported a narrower third-quarter net loss of $96.3 million, or $0.57 per share, significantly down from $163.1 million or $1.17 per share in the previous year. This improvement was primarily due...

    www.tokenpost.com•11/5/26•Bullish

    Vir Bio (VIR) Q3 2026 Earnings Call Transcript

    Vir Biotechnology reported its Q3 2026 financial results, highlighting a cash runway into the second half of 2028 and significant progress in its clinical pipeline...

    The Globe and Mail•11/5/26•Neutral

    Form 4 Vir Biotechnology Inc: Vanina de Verneuil (EVP, General Counsel, Corp Sec) For: 2 November

    This article reports on a Form 4 filing for Vir Biotechnology Inc, detailing an insider transaction by Vanina de Verneuil, EVP, General Counsel...

    Investing.com Canada•11/5/26•Neutral

    VIR Valuation and Fair Value

    P/E
    -9.7x
    Forward P/E
    4.3x
    P/FCF
    -14.6x
    P/B
    2.3x
    See GNG's fair value

    VIR Profitability: Margins, ROIC and FCF

    Operating margin
    30.7%
    Net margin
    -83.0%
    ROE
    -26.1%
    FCF margin
    -46.8%
    FCF yield
    -6.9%

    VIR Competitors

    CompanyTicker
    BioLife Solutions IncBLFS
    Certara IncCERT
    Replimune Group IncREPL
    AMN Healthcare Services IncAMN
    Harmony Biosciences HoldingsHRMY
    Galapagos NV ADRGLPG
    LeMaitre Vascular IncLMAT
    Trevi Therapeutics IncTRVI

    Sector: Healthcare

    VIR Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    3
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    VIR Bull Case vs Bear Case

    Bull case

    • VIR grew quarterly revenue 19582.0% year over year.
    • 100.0% of VIR's analyst ratings are Buy or Strong Buy.

    Bear case

    • VIR has a -83.0% net profit margin.
    • VIR beat EPS estimates in 37.5% of its last 8 reported quarters.

    VIR Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -39.7%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-2.23

    VIR Earnings Date

    VIR reports Feb 22, 2027, after the close. The date is confirmed.

    VIR Earnings Call

    The latest VIR earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    VIR ETF Holders

    GNG tracks 15 ETFs that hold VIR. The largest weights:

    1. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.60% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.30% of the fund
    3. iShares Biotechnology ETF (IBB), 0.11% of the fund
    4. Fidelity Enhanced Small Cap Core ETF (FESM), 0.10% of the fund
    5. iShares Core S&P Small-Cap ETF (IJR), 0.08% of the fund
    Open the ETF Stock Exposure tool for VIR

    See insider activity

    Frequently Asked Questions About VIR

    When does VIR report earnings?

    Vir Biotechnology Inc (VIR) is confirmed to report earnings on Feb 22, 2027.

    Does VIR pay dividends?

    Vir Biotechnology Inc (VIR) does not currently pay a regular dividend.

    What is VIR's market cap?

    Vir Biotechnology Inc (VIR) has a market capitalization of $1.86B with a current stock price of $12.21.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In